

PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. T90C3		SERIAL NO. 09/300,173		
LIST OF PRIOR ART CITED BY APPLICANT				APPLICANT YOUNGRO BYUN, et al.		RECEIVED JUL 20 1998		
				FILING DATE 04/27/99		GROUP 1633 TECH CENTER 1600/290		
U.S. PATENT DOCUMENTS								
EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AC							
OTHER PRIOR ART (Including Author, Title, Vol. No. Journal Name, First Page-Last Page (Year))								
KCF	AD		A. Leone-Bay, et al.; 4-[4-(2-Hydroxybenzoyl)amino]phenyl]butyric Acid as a Novel Oral Delivery Agent for Recombinant Human Growth Hormone, 39 J. Med. Chem. 2571-2578 (1996).					
KCF	AE		R. Altman, et al.; Oral Anticoagulant Treatment with and without Aspirin, 74(1) F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 506-510 (1995).					
KCF	AF		B. Koefoed, et al., Effect of Fixed Minidose Warfarin, Conventional Dose Warfarin and Aspirin on INR and Prothrombin Fragment 1 + 2 in Patients with Atrial Fibrillation, 77 (5) F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) 845-848 (1997).					
KCF	AG		P. Klement, et al., Hirudin causes more bleeding than heparin in a rabbit ear bleeding model, 132 J. Lab Clin Med 181-185 (1998).					
KCF	AH		R. Hull, et al.; Hirudin versus heparin and low-molecular-weight heparin: And the winner is ..., 132 J. Lab Clin Med 151-174 (1998).					
KCF	AI		G. E. Raskob, Msc. Low molecular weight heparin, heparin, and wafarin, 2 Current Opinion in Hematology 372-379 (1995).					
KCF	AJ		L. Wallentin, Unstable coronary artery disease - need for long term antithrombotic treatment, Aspirin alone is not sufficient, I would associate an anticoagulant, 33 Cardiovascular Research 292-294 (1997).					
KCF	AK		S. Milstein, et al., Partially unfolded proteins efficiently penetrate cell membranes - implications for oral drug delivery; 53 Journal of Controlled Release 259-267 (1998).					
KCF	AL		A. Leone-Bay, et al, The evolution of an oral heparin dosing solution, 22(8) Drugs of the Future 885-891 (1997).					
KCF	AM		A. Leone-Bay, et al., Oral Delivery of Sodium Cromolyn: Preliminary Studies <i>In Vivo</i> and <i>In Vitro</i> , 13(2) Pharmaceutical Research 222-226 (1995).					
KCF	AN		A. Leone-Bay, et al., N-Acylated $\alpha$ -Amino Acids as Novel Oral Delivery Agents for Proteins, 38 J. Med. Chem. 4263-4269 (1995).					
KCF	AO		E. Windsor & G. Cronheim, Gastro-Intestinal Absorption of Heparin and Synthetic Heparinoids, 190 Nature 263-264 (1961).					
KCF	AP		A. Leone-Bay, et al., Acylated non- $\alpha$ -amino acids as novel agents for the oral delivery of heparin sodium, USP, 50 Journal of Controlled Release 41-49 (1998).					
KCF	AQ		D. Brayden, et al., Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl) Amino] Caprylate in Rat <i>In Situ</i> Intestinal Instillations and in Caco-2 Monolayers, 14(12) Pharmaceutical Research 1772-1779 (1997).					
KCF	AR		A. Leone-Bay, et al., Synthesis and Evaluation of Compounds That Facilitate the Gastrointestinal Absorption of Heparin, 41 J. Med. Chem. 1163-1171, (1998).					
KCF	AS		A. Leone-Bay, et al., Microsphere Formation in a Series of Derivatized $\alpha$ -Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin, 38 J. Med. Chem. 4257-4262 (1995).					
EXAMINER				DATE CONSIDERED				
KCF Onoda				4-7-00				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

months not available  
KCF 4-7-00